Seeking Alpha
Recommended for you:
Value
Profile| Send Message|
( followers)  

Biotech is a hot sector with high risk and high rewards, and when a biotech company is starting to grow, the window to buy before it takes off can shrink pretty quick. Today, we focus on biotech companies with strong projected growth, focusing further on those that analysts consider a 'Strong Buy'.

EPS growth (earnings per share growth) illustrates the growth of earnings per share over time. The 1-Year Expected EPS Growth Rate is an annual growth estimate, where the growth projections are made by analysts, the company or other credible sources.

We first looked for biotechnology stocks. We then looked for companies with estimated high-growth, with 1-year projected EPS growth above 25%. We then looked for businesses that analysts rate as "Strong Buy" (mean recommendation < 2). We did not screen out any market caps.

Do you think these stocks are undervalued and have room to trade higher? Use our list to help with your own analysis.

1) Anika Therapeutics Inc. (NASDAQ:ANIK)

Sector:Healthcare
Industry:Biotechnology
Market Cap:$198.28M
Beta:1.44

Anika Therapeutics Inc. has a 1-Year Projected Earnings Per Share Growth Rate of 27.27%, and a Analysts' Rating of 1.00. The short interest was 1.60% as of 06/10/2012. Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers orthobiologics products for providing relief from the pain of osteoarthritis, and regenerating damaged tissue, such as cartilage defects; ORTHOVISC for the treatment of osteoarthritis of the knee and various joints; ORTHOVISC mini for the treatment of osteoarthritis in small joints; and MONOVISC, a single injection product used for the treatment of osteoarthritis in various joints.

2) Cerus Corporation (NASDAQ:CERS)

Sector:Healthcare
Industry:Biotechnology
Market Cap:$174.66M
Beta:2.32

Cerus Corporation has a 1-Year Projected Earnings Per Share Growth Rate of 33.30%, and a Analysts' Rating of 1.40. The short interest was 17.61% as of 06/10/2012. Cerus Corporation, together with its subsidiary, Cerus Europe B.V., engages in the development and commercialization of the INTERCEPT Blood System.

3) Cell Therapeutics, Inc. (NASDAQ:CTIC)

Sector:Healthcare
Industry:Biotechnology
Market Cap:$691.75M
Beta:5.39

Cell Therapeutics, Inc. has a 1-Year Projected Earnings Per Share Growth Rate of 82.60%, and a Analysts' Rating of 1.00. The short interest was 17.24% as of 06/10/2012. Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of drugs for the treatment of cancer. It is developing Pixuvri, a novel anthracycline derivative for the treatment of hematologic malignancies and solid tumors; OPAXIO, a chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate for treating ovarian, brain, esophageal, head, and neck cancers; Brostallicin, a synthetic DNA minor groove binding agent; and Bisplatinates, a platinum-based chemotherapy drug to treat various cancers.

4) Corcept Therapeutics Incorporated (NASDAQ:CORT)

Sector:Healthcare
Industry:Biotechnology
Market Cap:$377.56M
Beta:0.78

Corcept Therapeutics Incorporated has a 1-Year Projected Earnings Per Share Growth Rate of 94.70%, and a Analysts' Rating of 1.40. The short interest was 5.86% as of 06/10/2012. Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. It focuses on disorders that are associated with a steroid hormone called cortisol. The company focuses on commercializing Korlym (mifepristone) 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

5) Cornerstone Therapeutics Inc. (NASDAQ:CRTX)

Sector:Healthcare
Industry:Biotechnology
Market Cap:$135.76M
Beta:-0.66

Cornerstone Therapeutics Inc. has a 1-Year Projected Earnings Per Share Growth Rate of 281.82%, and a Analysts' Rating of 1.50. The short interest was 3.02% as of 06/10/2012. Cornerstone Therapeutics Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of prescription pharmaceutical drugs for the hospital, niche respiratory, and related specialty markets. The company offers CUROSURF, a natural lung surfactant used for the treatment of respiratory distress syndrome in premature infants; and ZYFLO CR and ZYFLO, which are leukotriene synthesis inhibitor drugs used for the prevention and chronic treatment of asthma in adults and children. The company's product pipeline also includes CRTX 080, a vasopressin receptor 2 antagonist lixivaptan used for the treatment of hyponatremia; CRTX 073, an anti-asthma product candidate used for the treatment of asthma; and CRTX 067, a cough/cold product candidate for the treatment of cough and cold.

6) BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Sector:Healthcare
Industry:Biotechnology
Market Cap:$114.49M
Beta:0.43

BioSpecifics Technologies Corp. has a 1-Year Projected Earnings Per Share Growth Rate of 31.00%, and a Analysts' Rating of 1.50. The short interest was 4.89% as of 06/10/2012. Biospecifics Technologies Corp., a biopharmaceutical company, involves in the development of an injectable collagenase for various indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase for clinical indications in Dupuytren's contracture, Peyronie's disease, and frozen shoulder.

7) Emergent BioSolutions, Inc. (NYSE:EBS)

Sector:Healthcare
Industry:Biotechnology
Market Cap:$505.16M
Beta:-0.06

Emergent BioSolutions, Inc. has a 1-Year Projected Earnings Per Share Growth Rate of 54.69%, and a Analysts' Rating of 1.20. The short interest was 4.33% as of 06/10/2012. Emergent BioSolutions, Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of vaccines and therapeutics for use in defense and commercial markets to healthcare providers and purchasers in the United States and internationally. It markets BioThrax, a vaccine for the prevention of anthrax disease. The company's products also include BioThrax PEP, which is in Phase III clinical trials; PreviThrax ands Anthrivig that are in Phase II clinical trials; and NuThrax and Thravixa, which are in Phase I clinical trials for the treatment of Anthrax.

*Company profiles were sourced from Finviz. Financial data was sourced from Yahoo Finance.

Source: 7 Growing Biotech Small Caps With Strong Analyst Confidence